CNR Institutional Research Information System

PIZZINI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.792
NA - Nord America 839
EU - Europa 497
SA - Sud America 397
AF - Africa 44
OC - Oceania 5
Totale 3.574
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 833
US - Stati Uniti d'America 785
CN - Cina 366
BR - Brasile 324
HK - Hong Kong 195
VN - Vietnam 187
IT - Italia 175
FR - Francia 127
KR - Corea 47
IN - India 35
GB - Regno Unito 33
DE - Germania 29
NL - Olanda 28
CA - Canada 26
AR - Argentina 23
BD - Bangladesh 23
FI - Finlandia 23
JP - Giappone 18
ID - Indonesia 15
EC - Ecuador 13
RU - Federazione Russa 12
PE - Perù 11
IE - Irlanda 10
PL - Polonia 9
ZA - Sudafrica 9
MX - Messico 8
VE - Venezuela 8
IQ - Iraq 7
MA - Marocco 7
PH - Filippine 7
SA - Arabia Saudita 7
TR - Turchia 7
AT - Austria 6
ES - Italia 6
IL - Israele 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
EG - Egitto 5
HR - Croazia 5
PK - Pakistan 5
SE - Svezia 5
UA - Ucraina 5
CR - Costa Rica 4
KE - Kenya 4
MY - Malesia 4
NP - Nepal 4
AL - Albania 3
AO - Angola 3
AU - Australia 3
BE - Belgio 3
ET - Etiopia 3
JM - Giamaica 3
NI - Nicaragua 3
PY - Paraguay 3
TN - Tunisia 3
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CL - Cile 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MT - Malta 2
OM - Oman 2
PA - Panama 2
RO - Romania 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AZ - Azerbaigian 1
CM - Camerun 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MR - Mauritania 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
PW - Palau 1
RS - Serbia 1
RW - Ruanda 1
SI - Slovenia 1
Totale 3.571
Salva come PNG Salva come JPEG
Città #
Singapore 528
Santa Clara 267
Hong Kong 194
Hefei 105
Lauterbourg 104
San Jose 83
Ho Chi Minh City 74
Beijing 67
Ashburn 62
Seoul 47
Hanoi 45
Los Angeles 45
Dallas 27
New York 27
São Paulo 25
Frankfurt am Main 14
Milan 13
Buffalo 11
Helsinki 10
Rio de Janeiro 10
Tokyo 10
Curitiba 9
Dublin 9
Düsseldorf 8
Toronto 8
Warsaw 8
Amsterdam 7
Biên Hòa 7
Da Nang 7
Lappeenranta 7
Orem 7
Rome 7
Baghdad 6
Belo Horizonte 6
Haiphong 6
Lima 6
Turku 6
Bengaluru 5
Chennai 5
Council Bluffs 5
Minamishinagawa 5
Quito 5
Zagreb 5
Atlanta 4
Belém 4
Boston 4
Brasília 4
Catania 4
Dhaka 4
Guayaquil 4
Ha Long 4
Jakarta 4
Johannesburg 4
London 4
Montreal 4
Naples 4
New Delhi 4
Paris 4
Paternò 4
Phoenix 4
Salvador 4
Sheffield 4
Stockholm 4
Vienna 4
Addis Ababa 3
Bologna 3
Cairo 3
Cape Town 3
City of London 3
Denver 3
Formosa 3
Houston 3
Hải Dương 3
Joinville 3
Juiz de Fora 3
Kathmandu 3
Krasnodar 3
Las Vegas 3
Magé 3
Manila 3
Montevideo 3
Mumbai 3
Munich 3
Nairobi 3
Ninh Bình 3
Philadelphia 3
Phủ Lý 3
Poplar 3
Porto Alegre 3
Pouso Alegre 3
Rabat 3
San Francisco 3
San José 3
Santo André 3
Sorocaba 3
Thái Bình 3
Volta Redonda 3
Abidjan 2
Aci Catena 2
At Tuwal 2
Totale 2.101
Salva come PNG Salva come JPEG
Nome #
Role of Gut Microbiota in Overweight Susceptibility in an Adult Population in Italy 117
8-hydroxy-2′-deoxyguanosine, a biomarker of oxidative DNA injury, in diabetic kidney disease 99
Osteopontin, death and cardiovascular events in stage G3–4 CKD patients: a joint model analysis 76
Il peptide natriuretico (BNP) è un biomarcatore della congestione polmonare nei pazienti in dialisi. 74
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients 69
Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients 68
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Acute Kidney Injury in Patients Undergoing Cardiopulmonary Bypass 67
Socioeconomic Status and Clinical Outcomes in Chronic Kidney Disease: Bootstrap Validation of a Simple Indicator 65
Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension 62
Osteopontin and Clinical Outcomes in Hemodialysis Patients 61
Plasma levels of myeloperoxidase and resistin independently predict mortality in dialysis patients 60
Inflammation biomarkers and inflammatory genes expression in metabolically healthy obese patients 60
Reducing salt intake by urine chloride self-measurement in non-compliant patients with chronic kidney disease followed in nephrology clinics: a randomized trial 57
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass 57
Perioperative Marinobufagenin (MBG) Measurement May Improve Acute Kidney Injury Risk Assessment in Patients Undergoing Major Cardiac Surgery: A Proof-of-Concept Study 55
Salt intake correlates with night systolic blood pressure in non-dialytic chronic kidney disease 53
CKD-MBD biomarkers and CKD progression: an analysis by the joint model 52
Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity 51
Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD 50
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study 47
Intact FGF23 and ?-klotho during acute inflammation/sepsis in CKD patients 47
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 46
FGF23 and the PTH response to paricalcitol in chronic kidney disease 46
Quality of life and kidney function in CKD patients: a longitudinal study 45
Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial 42
Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients 42
Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients 41
Neuropeptide Y and chronic kidney disease progression: a cohort study 41
Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients. 40
Procalcitonin and the inflammatory response to salt in essential hypertension: A randomized cross-over clinical trial 39
Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. 39
Resistin and all-cause and cardiovascular mortality: Effect modification by adiponectin in end-stage kidney disease patients 39
Long term predictors of cerebrovascular events in patients with end stage renal disease (ESRD). 38
Intact FGF23 and -klotho during acute inflammation/sepsis in CKD patients 37
L'obesità addominale interagisce con due citochine prodotte dal tessuto adiposo, Leptina ed Adiponectina, per predire il rischio di mortalità totale e cardiovascolare nei pazienti in dialisi. 36
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD) 36
I polimorfismi del gene ENPP1 si associano ad ipertrofia ventricolare sinistra ed alla funzione sistolica nei pazienti in dialisi. 36
Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial 36
Vitamin D and methylarginines in chronic kidney disease (CKD) 35
INDICES OF INSULIN RESISTANCE AND RISK OF TOTAL AND CARDIOVASCULAR MORTALITY IN DIALYSIS PATIENTS 34
Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients 34
Il rischio di progressione delle nefropatie croniche e mortalità: ruolo dell'Asymmetrical Di-Methil-Arginine (ADMA). 33
C-Reactive Protein and Interleukin-6 modify the risk of high levels of Asymmetric Dimethyl-Arginine (ADMA) for death and cardiovascular events in end stage renal diseases patients. 33
Leptin and biochemical markers of bone turnover in dialysis patients 31
Smoking and hyperparathyroidism in patients with end-stage renal disease (ESRD). 31
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in ckd patients. 30
FGF23 beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease patients. 30
Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study. 30
Vitamin D receptor activation by paricalcitol and insulin resistance in CKD 29
Low triiodothyronine and survival in end-stage renal disease. 28
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 27
Urotensin II is inversely related to markers of endothelial activation and inflammation and is an inverse predictor of incident cardiovascolar events in end stage renal disease (ESRD). 26
Vascular endothelial growth factor (VRGF) is a marker of left ventricular dysfunction and predicts mortality in hemodialysis (HD) patients. 26
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease 26
Urotensin II and cardiomyopathy in end-stage renal disease. 25
Vitamin D levels and patient outcome in chronic kidney disease. 25
L'iperparatiroidismo e il TNF-a come determinanti dell'incidenza di fratture nei pazienti in dialisi: uno studio di coorte. 25
Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease 25
Low triiodothyronine and survival in end stage renal disease (ESRD). 25
L'infiammazione amplifica il rischio di mortalità ed eventi cardiovascolari connesso ai livelli circolanti di dimetilarginina asimmetrica (ADMA) nei pazienti in dialisi. 25
Pattern evolutivo dei biomarcatori di infiammazione e dei fattori di rischio non tradizionali dopo trapianto renale. 24
Low Triiodothyronine and Cardiomyopathy in Patients with End-Stage Renal Disease (ESRD). 24
Association between resistin levels and all-cause and cardiovascular mortality: A new study and a systematic review and meta-analysis 24
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 24
Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels 24
Asymmetric Dimethylarginine (ADMA) Enzymatic Machinery and Adipokines Gene Expression in the Adipose Tissue in Stage 3-5 CKD patients. 24
Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients 24
Waist circumference modifies the relationship of adipose tissue cytochines leptin and adiponectin with all-cause and cardiovascular mortality in end stage renal disease (ESRD). 24
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end stage renal disease (ESRD). 24
Urotensin II partecipates in cardiovascular control in end stage renal disease (ESRD). 23
Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcome stage renal disease patients. 23
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 23
Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. 23
Vascular Endothelial Growth Factor, rimodellamento ventricolare sinistro e disfunzione sistolica nei pazienti in dialisi 23
Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial 22
Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides 22
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 22
Beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease (CKD) patients. 22
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in CKD patients. 22
L'ipotiroidismo subclinico si associa alla micro-infiammazione cronica e predice la mortalità nei pazienti in CAPD. Risultati di uno studio pilota di coorte. 22
Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease 20
Methylarginine enzymatic machinery and Leptin in adipose tissue in CKD patients. 20
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 20
Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. 20
Valore diagnostico per il basso turnover osseo del PTH dosato con metodi RIA di prima e seconda generazione. 20
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. 19
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. 19
Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study 19
Methylarginine enzymatic machinery and Leptin in adipose tissue in CKD patients. 18
Intact FGF23 and -klotho during acute inflammation/sepsis in CKD patients 18
Urotensina II e fattori di rischio cardiovascolare nei pazienti con insufficienza renale cronica in trattamento dialitico. 18
BRAIN NATRIURETIC PEPTIDE AS A BIOMARKER OF PULMONARY CONGESTION IN STAGE 5 CKD ON DIALYSIS 18
Smoking and hyperparathyroidism in patients with end stage renal disease (ESRD). 18
Livelli circolanti di tiiodrotironina (fT3) e mortalità nei pazienti in dialisi. 18
Thyroid sick syndrome e miocardiopatia nei pazienti con insufficienza renale cronica. 17
Which is the best inflammation marker? A comparative study based on multivariate modelling of mortality in end stage renal disease (ESRD) patients. 17
Diagnostic value for low bone turnover of first and second generation immuno-radiometric PTH assay. 17
Low Triiodothyronine (fT3): a new facet of inflammation in end stage renale disease (ESRD). 17
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). 17
Vascular endothelial growth factor, left ventricular remodeling and systolic dysfunction in end stage renal disease 17
Totale 3.489
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.562
article - articoli 8.366
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.928
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202439 0 0 0 0 0 0 0 0 32 0 7 0
2024/20251.487 6 12 115 91 307 27 33 103 44 58 376 315
2025/20262.150 96 199 226 313 412 87 346 159 95 138 79 0
Totale 3.676